Hims & Hers Health Inc. shares experienced a significant surge, reaching new record highs, after President-elect Donald Trump nominated Marty Makary to lead the Food and Drug Administration.
According to a report, Makary's appointment is expected to greatly benefit the company, as he is an executive at Sesame Inc., a startup involved in the sale of compounded GLP-1 weight loss drugs.
Hunterbrook Capital, which previously held a short bet on the online sales of Hims' compounded GLP-1 injections, has now shifted its position to a long stance on Hims shares.
The market's positive reaction reflects investor optimism about potential regulatory support for Hims & Hers under the new FDA leadership.